Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study

被引：0

作者：

Marme, F. ^{[1
]}

Hilpert, F. ^{[2
]}

Welslau, M. ^{[3
]}

Grabowski, J. P. ^{[4
,5
]}

Schneeweiss, A. ^{[6
,7
]}

Hartkopf, A. D. ^{[8
]}

Becker, S. ^{[9
]}

Runnebaum, I. ^{[10
]}

Bauerschlag, D. ^{[11
]}

Fasching, P. ^{[12
]}

Brandi, C. ^{[13
]}

Rehbein, J-K. ^{[14
]}

Glowik, R. ^{[15
]}

Sehouli, J. ^{[16
]}

机构：

[1] UMM Univ Klinikum Mannheim, Dept Gynecol Oncol, Med Fak, Mannheim, Germany

[2] Krankenhaus Jerusalem, Mammazentrum, Hamburg, Germany

[3] Klinikum Aschaffenburg, Hamato Onkol Schwerpunktpraxis, Aschaffenburg, Germany

[4] Univ Klin Charite, Dept Gynecol, Berlin, Germany

[5] Campus Virchow Klinikum, Berlin, Germany

[6] Univ Hosp, Div Gynecol Oncol, Natl Ctr Tumor Dis NCT, Gynecol Oncol, Heidelberg, Germany

[7] German Canc Res Ctr, Heidelberg, Germany

[8] Univ Hosp Tuebingen, Ctr Womens Hlth Dept, Tubingen, Germany

[9] Goethe Univ Frankfurt Main, Dept Obstet & Gynecol, Campus Westend, Frankfurt, Germany

[10] Friedrich Schiller Univ Jena, Gynecol & Reprod Med, Jena, Germany

[11] Univ Hosp UKSH, Gynecol Oncol, Kiel, Germany

[12] Univ Klinikum Erlangen, Dept Gynecol & Obstet, Erlangen, Germany

[13] Agaples Med Versorgungszentrum Frankfurt gGmbH, Frauenheilkunde Gynakol, Frankfurt, Germany

[14] Stadt Krankenhaus Kiel GmbH, Frauenklin, Kiel, Germany

[15] AstraZeneca GmbH, Med Affairs, Hamburg, Germany

[16] Charite, Gynecol, Berlin, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1979

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

802P

引用

页码：S535 / S536

页数：2

共 50 条

[21] Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
Banerjee, S.
Imbimbo, M.
Roxburgh, P.
Kim, J-W.
Kim, M. H.
Plummer, R.
Stemmer, S.
You, B.
Ferguson, M.
Penson, R. T.
O'Malley, D.
Meyer, K.
Gao, H.
Angell, H.
Nunes, A. Tablante
Domchek, S.
Drew, Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S788 - S789
[22] Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Cecere, Sabrina Chiara
Giannone, Gaia
Salutari, Vanda
Arenare, Laura
Lorusso, Domenica
Ronzino, Graziana
Lauria, Rossella
Cormio, Gennaro
Carella, Claudia
Scollo, Paolo
Ghizzoni, Viola
Raspagliesi, Francesco
Di Napoli, Marilena
Mazzoni, Enrica
Marchetti, Claudia
Bergamini, Alice
Orditura, Michele
Valabrega, Giorgio
Scambia, Giovanni
Maltese, Giuseppa
De Matteis, Elisabetta
Cardalesi, Cinzia
Loizzi, Vera
Boccia, Serena
Naglieri, Emanuele
Scandurra, Giuseppa
Pignata, Sandro
GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 38 - 44
[23] Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer
Vilming, Bente
Fallas Dahl, Jorgen
Bentzen, Anne Gry
Ingebrigtsen, Vibeke Anett
Berge Nilsen, Elisabeth
Vistad, Ingvild
Dorum, Anne
Solheim, Olesya
Bjorge, Line
Zucknick, Manuela
Aune, Guro
Lindemann, Kristina
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (12) : 1898 - 1905
[24] Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)
Kim, Se Ik
Lee, Jeong-Won
Kim, Kidong
Lee, Maria
Yoo, Jigeun
Choi, Min Chul
Hwangbo, Suhyun
Kwak, Young Hwa
Lee, Jong-Min
Shin, So-Jin
Shim, Seung-Hyuk
Kim, Min Kyu
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (06)
[25] NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer
Tucker, Helen
Charles, Zoe
Robertson, Janet
Adam, Jane
LANCET ONCOLOGY, 2016, 17 (03): : 277 - 278
[26] Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer
Moss, Haley A.
Perhanidis, Jessica A.
Havrilesky, Laura J.
Secord, Angeles Alvarez
GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 50 - 56
[27] Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Charlotte Bellier
Laurence Gladieff
Fanny Le Du
Dominique Berton
Charlotte Bonnard
Delphine Suau
Anne-Céline Richard
Ophélie Brenner
Amir Lahouegue
Gilles Freyer
Anne Floquet
Sophie Frank
Maria Kfoury
Drugs - Real World Outcomes, 2023, 10 : 207 - 213
[28] Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Bellier, Charlotte
Gladieff, Laurence
Le Du, Fanny
Berton, Dominique
Bonnard, Charlotte
Suau, Delphine
Richard, Anne-Celine
Brenner, Ophelie
Lahouegue, Amir
Freyer, Gilles
Floquet, Anne
Frank, Sophie
Kfoury, Maria
DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 207 - 213
[29] Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
Jonathan A Ledermann
Philipp Harter
Charlie Gourley
Michael Friedlander
Ignace Vergote
Gordon Rustin
Clare Scott
Werner Meier
Ronnie Shapira-Frommer
Tamar Safra
Daniela Matei
Anitra Fielding
Bryan Bennett
David Parry
Stuart Spencer
Helen Mann
Ursula Matulonis
British Journal of Cancer, 2016, 115 : 1313 - 1320
[30] Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
Ledermann, Jonathan A.
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Bennett, Bryan
Parry, David
Spencer, Stuart
Mann, Helen
Matulonis, Ursula
BRITISH JOURNAL OF CANCER, 2016, 115 (11) : 1313 - 1320

← 1 2 3 4 5 →